Quality of life and the experience of living with early-stage Alzheimer's disease

Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional...

Descripción completa

Detalles Bibliográficos
Autores: Villarejo-Galende, Alberto, Puig-Pijoan, Albert, Maurino, Jorge
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/55512
Acceso en línea:http://hdl.handle.net/10230/55512
http://dx.doi.org/10.3233/JAD-220696
Access Level:acceso abierto
Palabra clave:Alzheimer’s disease
Amyloid
Biomarkers
Cerebrospinal fluid
Magnetic resonance imaging
Tau proteins
White matter hyperintensities
White matter lesions
id ES_f545e86dfafbcb8e77f66f081c4349c2
oai_identifier_str oai:repositori.upf.edu:10230/55512
network_acronym_str ES
network_name_str España
repository_id_str
spelling Quality of life and the experience of living with early-stage Alzheimer's diseaseVillarejo-Galende, AlbertoPuig-Pijoan, AlbertMaurino, JorgeAlzheimer’s diseaseAmyloidBiomarkersCerebrospinal fluidMagnetic resonance imagingTau proteinsWhite matter hyperintensitiesWhite matter lesionsBackground: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.IOS Press202320232022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/55512http://dx.doi.org/10.3233/JAD-220696reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésJ Alzheimers Dis. 2022;90(2):719-26© 2022 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/555122026-06-12T07:21:37Z
dc.title.none.fl_str_mv Quality of life and the experience of living with early-stage Alzheimer's disease
title Quality of life and the experience of living with early-stage Alzheimer's disease
spellingShingle Quality of life and the experience of living with early-stage Alzheimer's disease
Villarejo-Galende, Alberto
Alzheimer’s disease
Amyloid
Biomarkers
Cerebrospinal fluid
Magnetic resonance imaging
Tau proteins
White matter hyperintensities
White matter lesions
title_short Quality of life and the experience of living with early-stage Alzheimer's disease
title_full Quality of life and the experience of living with early-stage Alzheimer's disease
title_fullStr Quality of life and the experience of living with early-stage Alzheimer's disease
title_full_unstemmed Quality of life and the experience of living with early-stage Alzheimer's disease
title_sort Quality of life and the experience of living with early-stage Alzheimer's disease
dc.creator.none.fl_str_mv Villarejo-Galende, Alberto
Puig-Pijoan, Albert
Maurino, Jorge
author Villarejo-Galende, Alberto
author_facet Villarejo-Galende, Alberto
Puig-Pijoan, Albert
Maurino, Jorge
author_role author
author2 Puig-Pijoan, Albert
Maurino, Jorge
author2_role author
author
dc.subject.none.fl_str_mv Alzheimer’s disease
Amyloid
Biomarkers
Cerebrospinal fluid
Magnetic resonance imaging
Tau proteins
White matter hyperintensities
White matter lesions
topic Alzheimer’s disease
Amyloid
Biomarkers
Cerebrospinal fluid
Magnetic resonance imaging
Tau proteins
White matter hyperintensities
White matter lesions
description Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/55512
http://dx.doi.org/10.3233/JAD-220696
url http://hdl.handle.net/10230/55512
http://dx.doi.org/10.3233/JAD-220696
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv J Alzheimers Dis. 2022;90(2):719-26
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv IOS Press
publisher.none.fl_str_mv IOS Press
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424574954733568
score 15,812429

Similares en LA Referencia